Deep Pharma Intelligence held a virtual event (November 23), which was a unique opportunity share our findings from a unique market study revealing R&D platforms for developing therapeutic cancer vaccines, the key players in each category, the science behind the development, and case studies illustrating opportunities and challenges of each research strategy. 

​

We presented our categorization of the 5 platforms — including relatively mainstream strategies — Neoantigen Platform, Tumor-associated Antigens Platform, Cellular Platform, and Oncolytic Viruses Platform — and the latest breakthrough and a potentially disruptive research strategy —  Antigenic Essence Platform.